Health Catalyst general counsel sells $140,973 in common stock

Benjamin Landry, Health Catalyst's General Counsel, sold $140,973 worth of the company's common stock in two transactions in November 2026. On November 11, he sold 70,000 shares at $1.4289 per share, and on November 12, he disposed of an additional 29,478 shares at $1.3892 each. These sales were made following a Rule 10b5-1 trading plan initiated on August 12, 2026.

After the sales, Landry still owned 251,894 shares of Health Catalyst common stock. The stock price has been volatile, currently trading at $1.51, down 36.8% year-to-date. Despite being undervalued according to InvestingPro's analysis, Health Catalyst faces near-term profitability challenges. The company reports surplus cash over debt on its balance sheet.

Health Catalyst's third-quarter 2026 financial results exceeded analysts' expectations, with adjusted earnings of $0.53 per share and revenue of $56.2 million. However, the stock declined during the regular session, indicating investor concerns about margins and churn.